新型侧向层析免疫分析法检测赛拉嗪的临床性能评估
本研究评估XYL500一步法赛拉嗪滥用检测试纸在152例尿液样本中检测赛拉嗪的能力,以LC-MS/MS为参考方法。结果显示诊断灵敏度74%、特异性98%、准确度82%,与阿片类镇痛药及常见药物交叉反应 minimal,仅1例假阳性。试纸可快速检测赛拉嗪,有助于监测摄入含赛拉嗪娱乐性药物的患者。
要点
- XYL500试纸检测赛拉嗪灵敏度74%、特异性98%、准确度82%。
- 可检出部分低至<10 ng/mL的赛拉嗪阳性样本。
- 与常见阿片类及药物交叉反应低,仅1例假阳性。
核心结论
- XYL500试纸可实现赛拉嗪的快速检测,有助于监测摄入含赛拉嗪娱乐性药物的患者并改善临床管理。
研究设计与样本
- 评估XYL500一步法赛拉嗪滥用检测试纸,在152例来自慢性阿片类镇痛治疗或物质使用障碍治疗患者的尿液样本中检测赛拉嗪,以LC-MS/MS为参考方法,并进行精密度、交叉反应、干扰和稳定性研究。
主要发现
- 混合患者样本在同日重复5次及连续3天检测中结果一致为阴性或阳性。
- 与LC-MS/MS相比,XYL500的诊断灵敏度为74%、特异性为98%、准确度为82%。
- XYL500在初评的104例LC-MS/MS阳性样本中检出77例,包括8例赛拉嗪水平<10 ng/mL的样本。
- 与其他阿片类镇痛药及常见药物交叉反应 minimal,仅出现1例假阳性;常见尿液污染物干扰可忽略。
- 标本在冷藏条件下稳定长达160天,室温下稳定长达80天。
关键数值与推荐
- 诊断灵敏度74%、特异性98%、准确度82%(以LC-MS/MS为参考方法,n=152尿液样本)。
- 104例LC-MS/MS阳性样本中检出77例,其中8例赛拉嗪<10 ng/mL。
- 冷藏稳定160天,室温稳定80天。
临床怎么用
- XYL500可用于快速检测尿液中的赛拉嗪,辅助监测摄入含赛拉嗪娱乐性药物的患者。
- 赛拉嗪中毒患者对纳洛酮治疗无反应,快速检测有助于识别并改善患者管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Xylazine is a potent sedative used in veterinary medicine. Recently, recreational drugs such as fentanyl have been found to contain xylazine, increasing the risk of respiratory depression and death. Despite a similar presentation to opioid overdose, patients who ingest xylazine do not respond to treatment with Narcan. Therefore, rapid detection of xylazine could improve patient management and prevent adverse outcomes. METHODS: We evaluated the XYL500 one-step xylazine drug of abuse test for its ability to detect xylazine in 152 urine samples from patients on chronic opioid therapy for pain management or in treatment for substance use disorder. Results were compared to LC-MS/MS as the reference method. Precision, cross-reactivity, interference and stability studies were performed. RESULTS: Pooled patient samples were consistently negative or positive when tested five times on the same day and over three days of testing. The diagnostic sensitivity, specificity and accuracy of the XYL500 assay were 74, 98, and 82 % respectively, as compared with LC-MS/MS. XYL500 detected 77 of the 104 LC-MS/MS positive samples identified in our initial evaluation, including some that contained low levels of xylazine (n=8), <10 ng/mL. Minimal cross-reactivity with other opioid analgesics and commonly encountered drugs was seen with only one false positive result. Interferences by common urine contaminants were negligible. Specimens were stable up to 160 days refrigerated and up to 80 days at room temperature. CONCLUSIONS: XYL500 allows for rapid detection of xylazine, illustrating its utility in monitoring patients who ingested recreational drugs containing the additive, xylazine, and its potential to improve patient management.
引用
- Contella L, Snyder ML, Kang P, et al. Clinical performance of a new lateral flow immunoassay for xylazine detection. Clin Chem Lab Med. 2024. PMID: 39392655. doi:10.1515/cclm-2024-0947
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。